Accessible Requires Authentication Published by De Gruyter May 6, 2015

Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases

Sergio Martín, Ainhoa Ruiz del Agua, Nerea Torres, Dora Pascual-Salcedo, Chamaida Plasencia, Begoña Ruiz-Argüello, Antonio Martínez, Rosaura Navarro and Daniel Nagore

Corresponding author: Daniel Nagore, Department of Research and Development, Progenika SA, ParqueTecnológico de Bizkaia 504, 48100, Derio, Spain, Phone: +34 944 064525, Fax: +34 944 064526, E-mail:


SM is supported by a Zabalduz predoctoral grant from UPV/EHU. The authors thank Simon Santa Cruz for critical review of the manuscript, and all the technicians from the R&D department for technical support.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial support: None declared.

Employment or leadership: AR, NT, BR, AM and DN are employed by Progenika Biopharma, S.A.

Honorarium: None declared.

Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947–55. Search in Google Scholar

2. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015;74:e16. Search in Google Scholar

3. Rosas J, Llinares-Tello F, de la Torre I, Santos-Ramirez C, Senabre-Gallego JM, Valor L, et al. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014;32:942–8. Search in Google Scholar

4. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955–60. Search in Google Scholar

5. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055–64. Search in Google Scholar

6. Krieckaert CL, Nair SC, Nurmohamed MT, van Dongen CJ, Lems WF, Lafeber FP, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2013;74:361–8. Search in Google Scholar

7. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919–27. Search in Google Scholar

8. Ruiz-Arguello B, del Agua AR, Torres N, Monasterio A, Martinez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:e287–9. Search in Google Scholar

9. Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, et al. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis 2014;73:2217–9. Search in Google Scholar

10. Vande CN, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765–71. Search in Google Scholar

Received: 2015-3-17
Accepted: 2015-4-14
Published Online: 2015-5-6
Published in Print: 2015-10-1

©2015 by De Gruyter